CLAIMS

1. A fast-dissolving pharmaceutical composition comprising micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter, referred to as "AS-3201").

2. The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

3. The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

4. The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 0.5 μm - about 3 μm.

5. A fast-dissolving pharmaceutical composition, which comprises micronized AS-3201 in a ratio of about 0.5 % by weight - 5 % by weight, a diluent in a ratio of about 51 % by weight - about 93.8 % by weight, a disintegrator in a ratio of about 5 % by weight - about 35 % by weight, a binder in a ratio of about 0.5 % by weight - about 5 % by weight, and a lubricant in a ratio of about 0.2 % by weight - about 4 % by weight, to the total weight of the pharmaceutical

composition.

6. The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 10 μm.

7. The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

8. The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 0.5 μm - about 3 μm.

9. The fast-dissolving pharmaceutical composition according to claim 5, which comprises a diluent in a ratio of about 59 % by weight - about 88 % by weight, a disintegrator in a ratio of about 10 % by weight - about 30 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

10. The fast-dissolving pharmaceutical composition according to claim 6, which comprises a diluent in a ratio of about 59 % by weight - about 88 % by weight, a disintegrator in a ratio of about 10 % by weight - about 30 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

11. The fast-dissolving pharmaceutical composition according to claim 7, which comprises a diluent in a ratio of about 59 % by weight - about 88 % by weight, a disintegrator in a ratio of about 10 % by weight - about 30 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

12. The fast-dissolving pharmaceutical composition according to claim 8, which comprises a diluent in a ratio of about 59 % by weight - about 88 % by weight, a disintegrator in a ratio of about 10 % by weight - about 30 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

13. A fast-dissolving pharmaceutical composition, which comprises micronized AS-3201 in a ratio of more than 5 % by weight and less than about 25% by weight, a diluent in a ratio of about 16 % by weight - about 84.3 % by weight, a disintegrator in a ratio of about 10 % by weight - about 50 % by weight, a binder in a ratio of about 0.5 % by weight - about 5 % by weight, and a lubricant in a ratio of about 0.2 % by weight - about 4 % by weight, to the total weight of the pharmaceutical composition.

14. The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the

micronized AS-3201 is less than about 10 μm.

15. The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

16. The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 0.5 μm - about 3 μm.

17. The fast-dissolving pharmaceutical composition according to claim 13, which comprises a diluent in a ratio of about 29 % by weight - about 73.5 % by weight, a disintegrator in a ratio of about 20 % by weight - about 40 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

18. The fast-dissolving pharmaceutical composition according to claim 14, which comprises a diluent in a ratio of about 29 % by weight - about 73.5 % by weight, a disintegrator in a ratio of about 20 % by weight - about 40 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

19. The fast-dissolving pharmaceutical composition according to claim 15, which comprises a diluent in a ratio of about 29 % by weight - about 73.5 % by weight, a

disintegrator in a ratio of about 20 % by weight - about 40 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

20. The fast-dissolving pharmaceutical composition according to claim 16, which comprises a diluent in a ratio of about 29 % by weight - about 73.5 % by weight, a disintegrator in a ratio of about 20 % by weight - about 40 % by weight, a binder in a ratio of about 1 % by weight - about 3 % by weight, and a lubricant in a ratio of about 0.5 % by weight - about 3 % by weight.

21. The fast-dissolving pharmaceutical composition according to claim 1, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

22. The fast-dissolving pharmaceutical composition according to claim 2, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

23. The fast-dissolving pharmaceutical composition according to claim 3, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

24. The fast-dissolving pharmaceutical composition according to claim 4, which has a dissolution percentage of

the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

25. The fast-dissolving pharmaceutical composition according to claim 5, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

26. The fast-dissolving pharmaceutical composition according to claim 6, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

27. The fast-dissolving pharmaceutical composition according to claim 7, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

28. The fast-dissolving pharmaceutical composition according to claim 8, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

29. The fast-dissolving pharmaceutical composition according to claim 9, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

30. The fast-dissolving pharmaceutical composition according to claim 10, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after

the start of the dissolution test.

31. The fast-dissolving pharmaceutical composition according to claim 11, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

32. The fast-dissolving pharmaceutical composition according to claim 12, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

33. The fast-dissolving pharmaceutical composition according to claim 13, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

34. The fast-dissolving pharmaceutical composition according to claim 14, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

35. The fast-dissolving pharmaceutical composition according to claim 15, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

36. The fast-dissolving pharmaceutical composition according to claim 16, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

37. The fast-dissolving pharmaceutical composition according to claim 17, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

38. The fast-dissolving pharmaceutical composition according to claim 18, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

39. The fast-dissolving pharmaceutical composition according to claim 19, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

40. The fast-dissolving pharmaceutical composition according to claim 20, which has a dissolution percentage of the active substance of 50 % or more for 15 minutes after the start of the dissolution test.

41. The fast-dissolving pharmaceutical composition according to claim 21, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

42. The fast-dissolving pharmaceutical composition according to claim 22, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

43. The fast-dissolving pharmaceutical composition

according to claim 23, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

44. The fast-dissolving pharmaceutical composition according to claim 24, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

45. The fast-dissolving pharmaceutical composition according to claim 25, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

46. The fast-dissolving pharmaceutical composition according to claim 26, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

47. The fast-dissolving pharmaceutical composition according to claim 27, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

48. The fast-dissolving pharmaceutical composition according to claim 28, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

49. The fast-dissolving pharmaceutical composition according to claim 29, which has a dissolution percentage

of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

50. The fast-dissolving pharmaceutical composition according to claim 30, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

51. The fast-dissolving pharmaceutical composition according to claim 31, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

52. The fast-dissolving pharmaceutical composition according to claim 32, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

53. The fast-dissolving pharmaceutical composition according to claim 33, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

54. The fast-dissolving pharmaceutical composition according to claim 34, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

55. The fast-dissolving pharmaceutical composition according to claim 35, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after

the start of the dissolution test.

56. The fast-dissolving pharmaceutical composition according to claim 36, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

57. The fast-dissolving pharmaceutical composition according to claim 37, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

58. The fast-dissolving pharmaceutical composition according to claim 38, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

59. The fast-dissolving pharmaceutical composition according to claim 39, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

60. The fast-dissolving pharmaceutical composition according to claim 40, which has a dissolution percentage of the active substance of 80 % or more for 15 minutes after the start of the dissolution test.

61. The fast-dissolving pharmaceutical composition according to claim 1, which contains as a stabilizer at least one acidic substance having an acidity more potent than that of AS-3201.

62. The fast-dissolving pharmaceutical composition according to claim 61, wherein the acidic substance is a member selected from the group consisting of citric acid, tartaric acid, maleic acid and phosphoric acid.